专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US3974275A 1,4-Dihydropyridine carboxylic acid esters useful as coronary vessel dilators and anti-hypertensives 失效
标题翻译：可用作冠状血管扩张剂和抗高血压药物的1,4-二氢吡啶羧酸酯
公开(公告)号：US3974275A
公开(公告)日：1976-08-10
申请号：US548395
申请日：1975-02-10
申请人： Friedrich Bossert , Horst Meyer , Wulf Vater
发明人： Friedrich Bossert , Horst Meyer , Wulf Vater
IPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , A61K31/535
CPC分类号： C07D401/04 , C07D401/14 , C07D405/14 , C07D409/14 , Y10S514/929
摘要： Certain 1,4-dihydropyridine carboxylic acid esters or their pharmaceutically acceptable non toxic salts are useful as coronary vessel dilators and antihypertensives.
摘要翻译：某些1,4-二氢吡啶羧酸酯或其药学上可接受的无毒盐可用作冠状血管扩张剂和抗高血压药。

62. 发明授权

US3951994A Tetrahydroindolizine derivatives 失效
标题翻译：四氢吲哚啉衍生物
公开(公告)号：US3951994A
公开(公告)日：1976-04-20
申请号：US468458
申请日：1974-05-09
申请人： Horst Meyer , Friedrich Bossert , Wulf Vater , Kurt Stoepel
发明人： Horst Meyer , Friedrich Bossert , Wulf Vater , Kurt Stoepel
IPC分类号： A61K31/395 , A61K31/44 , C07D455/02 , C07D471/04 , C07D213/57
CPC分类号： C07D471/04 , A61K31/395 , A61K31/44 , C07D455/02 , Y10S514/929
摘要： 1,4-Dihydropyridines bearing carbonyl functions in the 3- and 5-positions, being optionally substituted by lower alkyl in the 6-position, being substituted in the 4-position by lower alkyl, phenyl, substituted phenyl or a heterocyclic group, and being fused through the 1- and 2-positions to a five, six or seven membered cycloalkyl ring, one methylene group of which can be replaced by sulfur, oxygen imino or alkylimino, are antihypertensive agents and coronary vessel dilators. The compounds, of which 6-methyl-4-(3-nitrophenyl)-1,2-pentamethylene-1,4-dihydropyridine-3,5-dicarboxylic acid 3,5-diethyl ester is a representative embodiment, are prepared through condensation of an ylideneacetoacetic acid ester and a cyclic enamino carbonyl derivative.
摘要翻译：在3-位和5-位具有羰基官能团的1,4-二氢吡啶，任选被6位的低级烷基取代，在4-位被低级烷基，苯基，取代的苯基或杂环基取代，和通过1-和2-位融合成五，六或七元环烷基环，其中一个亚甲基可以被硫，氧亚氨基或烷基亚氨基取代，是抗高血压剂和冠状血管扩张剂。其中6-甲基-4-（3-硝基苯基）-1,2-戊烯-1,4-二氢吡啶-3,5-二羧酸3,5-二乙酯的代表性实施例是通过缩合的亚乙酰乙酸酯和环状氨基羰基衍生物。

63. 发明授权

US3932646A Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate 失效
标题翻译：含有1,4-二氢吡啶3,5-二羧酸酯的不对称酯的药物组合物
公开(公告)号：US3932646A
公开(公告)日：1976-01-13
申请号：US399387
申请日：1973-09-21
申请人： Horst Meyer , Friedrich Bossert , Wulf Vater , Kurt Stoepel
发明人： Horst Meyer , Friedrich Bossert , Wulf Vater , Kurt Stoepel
IPC分类号： A61K31/455
CPC分类号： A61K31/455 , Y10S514/929
摘要： Pharmaceutical compositions containing unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylate as the active ingredient and methods of using same. The said ingredients are unsymmetrical esters of 1,4-dihydropyridine 3,5-dicarboxylic acid which are substituted at position-4 of the dihydropyridine ring by phenyl or a substituted phenyl moiety. The compositions have cardiovascular activity which makes them useful for effecting coronary vascular dilation and in the treatment of hypertension.
摘要翻译：含有1,4-二氢吡啶3,5-二羧酸不对称酯作为活性成分的药物组合物及其使用方法。所述成分是1,4-二氢吡啶3,5-二羧酸的不对称酯，它们在二氢吡啶环的4位被苯基或取代的苯基部分取代。该组合物具有心血管活性，使其可用于实现冠状动脉血管扩张和治疗高血压。

64. 发明授权

US08399529B2 Method of homogenization and, optionally, analysis for processing moist noble metal-containing recycling materials with an unknown noble metal content 有权
标题翻译：均质化方法，以及任选地分析用于处理具有未知贵金属含量的含贵金属的回收材料
公开(公告)号：US08399529B2
公开(公告)日：2013-03-19
申请号：US11470659
申请日：2006-09-07
申请人： Christian Mock , Horst Meyer , Matthias Grehl , Jochen Schleβmann , Martin Stettner
发明人： Christian Mock , Horst Meyer , Matthias Grehl , Jochen Schleβmann , Martin Stettner
IPC分类号： C08J11/04
CPC分类号： G01N1/286 , C22B1/005 , C22B11/021 , C22B11/042 , G01N2001/2866 , Y02P10/214 , Y02P10/234
摘要： For processing of noble metal-containing, moist recycling materials with an unknown noble metal content (hereinafter called “batch”), a moisture-binding agent is added for homogenisation and the batch is mixed with comminution of optionally pre-sent agglomerates to form a free-flowing and homogenous powder. Optionally, the following takes place subsequently for analysis: A at least one representative, volume-reduced sample is taken first of all, B the sample is dried, C the sample is optionally divided further and D the sample is analyzed and the noble metal content of the batch is calculated on the basis of the data a previously known or pre-calculated quantity of the moisture-binding agent being added before sampling (step A).
摘要翻译：对于具有未知贵金属含量（以下称为批次）的含贵金属的潮湿回收材料的加工，加入湿粘结剂用于均化，并将批料与任选的预先发送的附聚物粉碎混合以形成自由基，流动均匀的粉末。任选地，随后进行以下分析：首先至少采用一个代表性的体积减少的样品，B样品被干燥，C，任选地分开样品，D分析样品，并且贵金属含量基于在采样之前添加的先前已知或预先计算的水分结合剂的数据的数据（步骤A）来计算。

65. 发明授权

US07999126B2 Palladium(0)-dibenzylidene acetone complexes 有权
标题翻译：钯（0） - 二亚苄基丙酮络合物
公开(公告)号：US07999126B2
公开(公告)日：2011-08-16
申请号：US12595628
申请日：2008-04-09
申请人： Richard Walter , Horst Meyer , Steffen Voss
发明人： Richard Walter , Horst Meyer , Steffen Voss
IPC分类号： C07F15/00
CPC分类号： C07F15/006
摘要： Palladium(0)-dibenzylidene acetone complexes Pdx(dba)y, with y/x being from 1.5 to 3, are provided according to the invention at a purity of at least 99.5 wt. %. The use of said Pdx(dba)y complexes according to the invention is for determining their stoichiometry by means of elemental analysis. In the method for the production of Pdx(dba)y complexes from a Pd-containing educt and dibenzylidene acetone (dba) in alcohol, according to the invention a solution of the dba in alcohol pre-heated to more than 40° C. is provided first and then the Pd-containing educt is added to the pre-heated solution upon which the complexes are precipitated by a base.
摘要翻译：钯（0） - 二亚苄基丙酮络合物Pd x（dba）y，其y / x为1.5至3，根据本发明提供纯度至少为99.5wt。％。根据本发明使用所述Pdx（dba）y配合物是通过元素分析来确定其化学计量。在根据本发明的用于从含Pd溶剂和二亚苄基丙酮（dba）中生产Pdx（dba）y络合物的方法中，根据本发明，预先加热至40℃以上的酒精中的dba溶液为首先提供，然后将含Pd的离子加入到其中络合物被碱沉淀的预热溶液中。

66. 发明申请

US20100167408A1 Palladium(0)-Dibenzylidene Acetone Complexes 有权
标题翻译：钯（0） - 二亚苄基丙酮络合物
公开(公告)号：US20100167408A1
公开(公告)日：2010-07-01
申请号：US12595628
申请日：2008-04-09
申请人： Richard Walter , Horst Meyer , Steffen Voss
发明人： Richard Walter , Horst Meyer , Steffen Voss
IPC分类号： G01N33/20 , C07F15/00
CPC分类号： C07F15/006
摘要： Palladium(0)-dibenzylidene acetone complexes Pdx(dba)y, with y/x being from 1.5 to 3, are provided according to the invention at a purity of at least 99.5 wt. %. The use of said Pdx(dba)y complexes according to the invention is for determining their stoichiometry by means of elemental analysis. In the method for the production of Pdx(dba)y complexes from a Pd-containing educt and dibenzylidene acetone (dba) in alcohol, according to the invention a solution of the dba in alcohol pre-heated to more than 40° C. is provided first and then the Pd-containing educt is added to the pre-heated solution upon which the complexes are precipitated by a base.
摘要翻译：钯（0） - 二亚苄基丙酮络合物Pd x（dba）y，其y / x为1.5至3，根据本发明提供纯度至少为99.5wt。％。根据本发明使用所述Pdx（dba）y配合物是通过元素分析来确定其化学计量。在根据本发明的用于从含Pd溶剂和二亚苄基丙酮（dba）中生产Pdx（dba）y络合物的方法中，根据本发明，预先加热至40℃以上的酒精中的dba溶液为首先提供，然后将含Pd的离子加入到其中络合物被碱沉淀的预热溶液中。

67. 发明授权

US07145027B2 Method for producing chlorotris(triphenylphosphine) rhodium (i) 有权
标题翻译：氯三（三苯基膦）铑的制备方法（i）
公开(公告)号：US07145027B2
公开(公告)日：2006-12-05
申请号：US10526912
申请日：2003-07-08
申请人： Richard Walter , Horst Meyer
发明人： Richard Walter , Horst Meyer
IPC分类号： C07F15/00 , B01J31/00
CPC分类号： C07F15/008
摘要： A process is described for the manufacture of chlorotris(triphenylphosphine)-rhodium(1) by means of causing a reaction of RhCl3 solution with triphenylphosphin in mixtures of C2–C5 alcohols with watersubsequently cooling down and filtering the crystalline precipitate obtained characterized in that the mixture of the reactants is handled in such a way that B is warmed up to 75° C., and C is maintained at 80 to 110° C. The technique leads to improvements in the yield and quality of the crystals obtained.
摘要翻译：描述了通过使C 2 -C 5醇与水的混合物中的三氯化膦与三苯基膦的反应随后冷却和过滤的方法来描述制备氯三（三苯基膦） - 铑（1）的方法得到的结晶沉淀物的特征在于反应物的混合物的处理方式使得B被加热至75℃，C保持在80至110℃。该技术导致产率和质量的提高的晶体。

68. 发明授权

US4798840A Coronary-active fluorine-containing 1,4-dihydropyridines 失效
标题翻译：冠状活性含氟1,4-二氢吡啶类
公开(公告)号：US4798840A
公开(公告)日：1989-01-17
申请号：US937764
申请日：1986-12-04
申请人： Egbert Wehinger , Horst Meyer , Andreas Knorr , Stanislav Kazda
发明人： Egbert Wehinger , Horst Meyer , Andreas Knorr , Stanislav Kazda
IPC分类号： A61K31/4427 , A61K31/455 , A61P9/08 , A61P9/12 , C07D211/90 , C07D401/04 , C07D401/06 , C07D401/12 , C07D413/04
CPC分类号： C07D401/04 , C07D211/90 , C07D401/06 , C07D401/12 , C07D413/04
摘要： Hypotensive long-acting 1,4-dihydropyridines of the formula ##STR1## in which R.sup.1 is phenyl or heterocyclic,R.sup.2, R.sup.3, R.sup.4 and R.sup.5 have the usual definitions in such compounds,R.sup.6 represents hydrogen or a lower alkyl radical or the trifluoromethyl group,R.sup.7 and R.sup.8 each denote a hydrogen atom or a fluorine atom,n.gtoreq.1 andm.gtoreq.0, and the sum of n and m must be a least 4, andX represents a single bond, an oxygen atom or the group --N(alkyl)--O.sub.2 S--,or pharmacologically acceptable acid addition salts thereof.
摘要翻译： R1为苯基或杂环的低级长效1,4-二氢吡啶类化合物，其中R 1为苯基或杂环基，R 2，R 3，R 4和R 5在这些化合物中具有通常的定义，R 6表示氢或低级烷基或三氟甲基，R7和R8各自表示氢原子或氟原子，n> = = 1且m≥0，n和m的和必须为4以下，X表示单键，氧原子或基团-N（烷基）-O2S-或其药理学上可接受的酸加成盐。

69. 发明授权

US4621082A Pyridopyrimidines, pharmaceutical compositions and use 失效
标题翻译：吡啶并嘧啶，药物组合物和用途
公开(公告)号：US4621082A
公开(公告)日：1986-11-04
申请号：US816594
申请日：1986-01-07
申请人： Horst Meyer , Egbert Wehinger , Bernward Garthoff , Stanislav Kazda
发明人： Horst Meyer , Egbert Wehinger , Bernward Garthoff , Stanislav Kazda
IPC分类号： A61K31/435 , A61P7/10 , A61P9/08 , A61P13/02 , A61P15/00 , C07D211/90 , C07D471/04 , A61K31/505 , A61K31/535
CPC分类号： C07D471/04 , C07D211/90
摘要： Pyridopyrimidines of the formula ##STR1## in which R.sup.1 is optionally substituted aryl or heterocyclic,exhibit circulation active properties, especially renal vasodilating and diuretic action.
摘要翻译：其中R1是任选取代的芳基或杂环的式“IMAGE”的吡啶并嘧啶具有循环活性，特别是肾血管扩张和利尿作用。

70. 发明授权

US4532248A Method of combatting coronary and vascular diseases 失效
标题翻译：打击冠心病和血管疾病的方法
公开(公告)号：US4532248A
公开(公告)日：1985-07-30
申请号：US398034
申请日：1982-07-14
申请人： Gerhard Franckowiak , Horst Boshagen , Friedrich Bossert , Siegfried Goldmann , Horst Meyer , Egbert Wehinger , Jurgen Stoltefuss , Matthias Schramm , Gunter Thomas , Robertson Towart
发明人： Gerhard Franckowiak , Horst Boshagen , Friedrich Bossert , Siegfried Goldmann , Horst Meyer , Egbert Wehinger , Jurgen Stoltefuss , Matthias Schramm , Gunter Thomas , Robertson Towart
IPC分类号： A61K31/435 , A61K31/4427 , A61K31/4433 , A61K31/445 , A61K31/451 , A61K31/455 , A61K31/47 , A61K31/495 , A61K31/535 , A61P3/00 , A61P3/08 , A61P7/10 , A61P9/02 , A61P9/04 , A61P29/00 , C07D211/00 , C07D211/82 , C07D211/84 , C07D211/90 , C07D213/00 , C07D221/00 , C07D307/00 , C07D311/00 , C07D333/00 , C07D401/04 , C07D401/12 , C07D401/14 , C07D409/04 , C07D471/04 , C07D491/04 , C07D491/044 , C07D491/048 , C07D491/052 , C07D491/10 , C07D491/107 , C07D498/04 , A61K31/44
CPC分类号： C07D401/04 , C07D211/84 , C07D211/90 , C07D409/04 , C07D471/04 , C07D491/04 , C07D491/10
摘要： 1,4-Dihydropyridines of the formula ##STR1## in which n is 0,1 or 2, andR.sup.1 to R.sup.7 can have a wide variety of meanings, which possess inotropic action, and many of which are new, are useful in increasing the influx of Ca.sup.++ into cells, particularly in combatting coronary and vascular diseases, hypertension swelling in the mucous membranes and diseases involving increased blood sugar or an incorrect salt and fluid balance.
摘要翻译：其中n为0,1或2，且R1至R7可以具有多种含义，其具有各向异性作用，并且其中许多是新的，可用于增加其中n为0,1或2的1,4-二氢吡啶 Ca ++进入细胞，特别是与冠状动脉和血管疾病的对抗，粘膜中的高血压肿胀和血糖升高或不正确的盐和液体平衡的疾病。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式